

# Liver Matters

Observational Research Capabilities in Liver



October 2024





Agile, efficient evidence generation with a technology-first approach

uncompromised quality  
less resources

# We specialize in observational research.

- ✓ We bring the best team to the table for every sponsor
- ✓ Data in our platform have been used with regulators, including the FDA and EMA
- ✓ We have run everything from Natural History Studies to Post-Marketing Safety Studies
- ✓ We have worked with big pharma and biotechs
- ✓ >10 year track record

# Rare, Cancer, and Chronic  
Disease Conditions



# Sites  
Globally



# Patients  
Globally



Blue-chip customers:  
8 of top 10 Pharma



# Peer Reviewed  
Publications



# Our bold vision for

Revolutionize liver research using regulatory-grade\* real-world data


We are intent on pushing the frontiers of liver research across rare and chronic liver diseases by bringing together a pre-competitive consortium of pharma collaborators to create a geographically diverse liver-focused registry across North America and Europe.



\* The Pulse platform meets all current privacy requirements, including HIPAA, GDPR, SOC 2 Type 2, 21 CFR 11, and ISO27001 certification


# Enable RWD collection in multiple diseases of interest across your pipeline

- The Pulse platform has been utilized with a large global pharma to assess pruritis associated with PBC in the US and Germany.
- With an established platform and set of common data elements established, **Pulse is seeking pharma sponsors to support the work across liver disease, globally.**



# A robust foundation of real-world data


By launching with ePROs and providing optionality to expand clinical, phenotypic and biomarker data, we offer sponsors a pragmatic platform to augment research, understanding of disease, clinical trial performance, and treatment effectiveness.



*\*Registry design at launch to be finalized based on confirmed number of sponsors and launch sponsor priorities.*

# Flexible data access model

Pre-set aggregate data access packages to support multi-year evidence work, each including various data access options described below.




1 Dashboards

2 Reports

3 Publications

...and more

- Continuously available descriptive displays of real-time data
- Pulse biostatisticians develop and run analytics that fulfill specific research questions and time requirements
- Pulse has proven and exceptional medical writing capabilities for abstracts and support with manuscripts.
- Consortium sponsors may fund custom sub-studies and additional data access.



Note: Example dashboard from Pulse's global melanoma registry.

# Sub-study ready

Configuration is part of our DNA. To support sub-studies of interest to sponsors, the Pulse platform has been natively built to be configured with ease with the depth of study workflow required by sponsors.

Tailor look and feel for the sub-study

Collect additional data elements (ePROs, eCOAs, and eCRFs)

Add consent or assent workflows, including pediatric/caregiver workflows

Ingest and harmonize retrospective data

Add and manage file uploads

Clinically validate patient-reported data remotely

Configure Adverse Event Triggers/Notifications

Integrate real-world and randomize control trial data via advanced modeling and AI/ML



# We enable evidence generation throughout the lifecycle of a molecule

## Pre-Clinical



- Natural history data
- Deepen relationships with expert researchers
- Inform pipeline prioritization

## Early Clinical



- Inform trial design
- Develop clinical endpoints
- Define and create comparator arms

## Late Clinical and Post-Approval



- Capture QoL data
- External control arms
- Market Access studies
- Reimbursement & Payor evidence
- Long-Term Follow-Up
- Safety and REMS studies